Balar AV et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: Results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol 2022;[Online ahead of print]. Abstract

Daneshmand S et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: A phase I trial. Urol Oncol 2022;40(7):344.e1-9. Abstract

Galsky MD et al. Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). ASCO GU 2023;Abstract 447.

Galsky MD et al. Extended follow-up results from the CheckMate 274 trial. ASCO GU 2023;Abstract LBA443.

Galsky MD et al. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). J Clin Oncol 2022:40(6S):438. Abstract

Guercio BJ et al. Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). ASCO GU 2022;Abstract 498.

Hoimes CJ et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol 2023;41(1):22-31. Abstract

Kim R et al. Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy. ASCO GU 2022;Abstract 551.

Loriot Y et al. Erdafitinib in locally advanced and metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338-48. Abstract

Loriot Y et al. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. J Clin Oncol 2022;40(6S):432. Abstract

Meric-Bernstam F et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. Cancer Discov 2022;12(2):402-15. Abstract

Powles T et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). ASGO GU 2022;Abstract TPS579.

Powles T et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial. J Clin Oncol 2022;40(6):487. Abstract

Powles T et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. ASCO GU 2021;Abstract 393.

Rosenberg JE et al. Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU). J Clin Oncol 2023;41(1):43-53. Abstract

Rosenberg JE et al. Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.

Sheng X et al. RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. ASCO 2022;Abstract 4520.

Siefker-Radtke AO et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract

Sridhar A et al. Major stressful events and risk of developing head/neck and pancreatic cancer. ASCO 2022;Abstract 12128.

Sternberg CN et al. FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/ 3 mRNA expression. J Clin Oncol 2023;41(3):629-39. Abstract

Valenza et al. Emerging treatment landscape of non-muscle invasive bladder cancer. Expert Opin Biol Ther 2022;22(6):717-34. Abstract

Xu H et al. A phase II study of RC48-ADC in HER2-netagive patients with locally advanced or metastatic urothelial carcinoma. ASCO 2022;Abstract 4519.